Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385083 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL3382661 | 0.87 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL13630712 | 0.87 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL3381236 | 0.85 | GPR119 (0.41) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL13617533 | 0.85 | GPR119 (0.41) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL13617537 | 0.85 | SETD7 (0.32) | SETD7 | |
| SCHEMBL3379108 | 0.85 | SETD7 (0.32) | SETD7 | |
| SCHEMBL3382099 | 0.79 | CHRM1 (0.37) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3382566 | 0.73 | TERT (0.34) | HSD11B1SETD7 | |
| SCHEMBL3382744 | 0.72 | SETD7 (0.32) | SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | CHRM2 89/4885CHRM1 60/4885CHRM3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.